Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
FLGT Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals several negative factors: a significant decline in revenue, reduced gross margins, increased losses, and a major customer's transition impacting sales. Despite management's confidence in margin recovery and ongoing product development, the financial performance remains weak. The Q&A section showed uncertainty regarding future growth and a lack of clarity on strategic impacts, such as the CMS CRUSH initiative. While share repurchases and cash reserves are positive, they don't offset the broader negative sentiment. Given these factors, a negative stock price movement is likely in the short term.
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture: strong revenue growth in several segments and improved margins are positive, but significant customer loss and increased expenses are concerning. The optimistic guidance and strategic initiatives in AI and genomics are promising, yet the conservative revenue loss estimate and expected cash burn are potential negatives. The Q&A reveals management's confidence in future growth but lacks clarity on cost synergies and AI strategy. Given these factors, the stock price reaction is likely to be neutral over the next two weeks.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call indicates strong financial performance with improved gross margins, reduced operating expenses, and a positive adjusted EBITDA. Revenue guidance has been raised, and there is optimism about future growth due to new product launches and market expansion. While management avoided specific guidance on some aspects, the overall sentiment is positive due to strategic advancements and financial health improvements. The Q&A session provided reassurance on collection issues and highlighted growth drivers, supporting a positive outlook for stock price movement.
FLGT Slides
FLGT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
